Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...
Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...
Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed ...
Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.
The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback